Startup · $60m raised
San Francisco Bay Area
Every investor coverage indicates participated in a round Allay Therapeutics raised.
| Investor | Rounds | Invested |
|---|---|---|
| Arboretum Ventures | Series C | - |
| Brandon Capital Partners | Series C | - |
| New Enterprise Associates | Series C | - |
| Pavilion Capital | Series C | - |
| Temasek | Series C | - |
| Vertex Growth | Series C | - |
| Vertex Ventures HC | Series C | - |
| WTT Investment Ltd | Series C | - |
Investors whose own portfolio pages list Allay Therapeutics, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon BioCatalyst | its portfolio page ↗ |
Companies Allay Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Adam Gridley | Chief Executive Officer | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Allay Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
US-Singapore biotech Allay Therapeutics has closed a $60 million Series C round led by Arboretum Ventures, with several healthcare investors taking part, to advance its long-acting post-surgical pain candidate into late-stage trials.